体重指数对儿童和成人甲型H1N1流感大流行疫苗免疫原性的影响。
Impact of body mass index on immunogenicity of pandemic H1N1 vaccine in children and adults.
作者信息
Callahan S Todd, Wolff Mark, Hill Heather R, Edwards Kathryn M
机构信息
Division of Adolescent and Young Adult Health, Department of Pediatrics Vanderbilt Vaccine Research Program, Department of Pediatrics, Vanderbilt University School of Medicine, Nashville, Tennessee.
EMMES Corp., Rockville, Maryland.
出版信息
J Infect Dis. 2014 Oct 15;210(8):1270-4. doi: 10.1093/infdis/jiu245. Epub 2014 May 1.
Abstract
Obesity emerged as a risk factor for morbidity and mortality related to 2009 pandemic influenza A (H1N1) infection. However, few studies examine the immune responses to H1N1 vaccine among children and adults of various body mass indices (BMI). Pooling data from 3 trials of unadjuvanted split-virus H1N1 A/California/07/2009 influenza vaccines, we analyzed serologic responses of participants stratified by BMI grouping. A single vaccine dose produced higher hemagglutination inhibition antibody titers at day 21 in obese compared to nonobese adults, but there were no significant differences in responses to H1N1 vaccine among children or adults of various BMI following 2 doses.
摘要
肥胖已成为与2009年甲型H1N1大流行性流感感染相关的发病和死亡风险因素。然而，很少有研究考察不同体重指数（BMI）的儿童和成人对H1N1疫苗的免疫反应。我们汇总了3项关于无佐剂裂解病毒H1N1 A/加利福尼亚/07/2009流感疫苗试验的数据，分析了按BMI分组的参与者的血清学反应。与非肥胖成人相比，肥胖成人在第21天时单剂疫苗产生的血凝抑制抗体滴度更高，但2剂疫苗接种后，不同BMI的儿童或成人对H1N1疫苗的反应没有显著差异。
相似文献
1
Impact of body mass index on immunogenicity of pandemic H1N1 vaccine in children and adults.
J Infect Dis. 2014 Oct 15;210(8):1270-4. doi: 10.1093/infdis/jiu245. Epub 2014 May 1.
2
Comparison of the long-term immunogenicity of two pandemic influenza A/H1N1 2009 vaccines, the MF59-adjuvanted and unadjuvanted vaccines, in adults.
Clin Vaccine Immunol. 2012 May;19(5):638-41. doi: 10.1128/CVI.00026-12. Epub 2012 Feb 29.
3
Pre-vaccination immunity and immune responses to a cell culture-derived whole-virus H1N1 vaccine are similar to a seasonal influenza vaccine.
Vaccine. 2012 Jun 22;30(30):4543-51. doi: 10.1016/j.vaccine.2012.03.061. Epub 2012 Apr 1.
4
Immunogenicity of a monovalent 2009 influenza A(H1N1) vaccine in infants and children: a randomized trial.
JAMA. 2010 Jan 6;303(1):37-46. doi: 10.1001/jama.2009.1911. Epub 2009 Dec 21.
5
Immunogenicity and safety of a monovalent vaccine for the 2009 pandemic influenza virus A (H1N1) in children and adolescents.
Vaccine. 2010 Aug 16;28(36):5864-70. doi: 10.1016/j.vaccine.2010.06.059. Epub 2010 Jul 13.
6
Safety and immune responses in children after concurrent or sequential 2009 H1N1 and 2009-2010 seasonal trivalent influenza vaccinations.
J Infect Dis. 2012 Sep 15;206(6):828-37. doi: 10.1093/infdis/jis445. Epub 2012 Jul 16.
7
Safety and immunogenicity of 2009 pandemic influenza A H1N1 vaccines in China: a multicentre, double-blind, randomised, placebo-controlled trial.
Lancet. 2010 Jan 2;375(9708):56-66. doi: 10.1016/S0140-6736(09)62003-1. Epub 2009 Dec 15.
8
Report of the 7th meeting on Evaluation of Pandemic Influenza Vaccines in Clinical Trials, World Health Organization, Geneva, 17-18 February 2011.
Vaccine. 2011 Oct 13;29(44):7579-86. doi: 10.1016/j.vaccine.2011.08.031. Epub 2011 Aug 19.
9
Clinical and immune responses to inactivated influenza A(H1N1)pdm09 vaccine in children.
Pediatr Infect Dis J. 2014 Aug;33(8):865-71. doi: 10.1097/INF.0000000000000329.
10
Immunogenicity and safety of a 2009 pandemic influenza A (H1N1) monovalent vaccine in Chinese infants aged 6-35 months: a randomized, double-blind, controlled phase I clinical trial.
Influenza Other Respir Viruses. 2013 Nov;7(6):1297-307. doi: 10.1111/irv.12028. Epub 2012 Nov 8.
引用本文的文献
1
Exploring How Adipose Tissue, Obesity, and Gender Influence the Immune Response to Vaccines: A Comprehensive Narrative Review.
Int J Mol Sci. 2025 Jan 20;26(2):862. doi: 10.3390/ijms26020862.
2
How does geographical diversity shape vaccine efficacy?
Clin Exp Vaccine Res. 2024 Oct;13(4):271-300. doi: 10.7774/cevr.2024.13.4.271. Epub 2024 Oct 31.
3
Elevated body mass index is not significantly associated with reduced influenza vaccine effectiveness.
Sci Rep. 2024 Sep 13;14(1):21466. doi: 10.1038/s41598-024-72081-z.
4
Impact of clinico-biochemical and inflammatory biomarkers on the immunogenicity and efficacy of SARS-CoV-2 adenoviral vaccine: a longitudinal study.
J Circ Biomark. 2023 Sep 20;12:34-43. doi: 10.33393/jcb.2023.2480. eCollection 2023 Jan-Dec.
5
Assessment of Humoral Immune Responses to Repeated Influenza Vaccination in a Multiyear Cohort: A 5-Year Follow-up.
J Infect Dis. 2024 Feb 14;229(2):322-326. doi: 10.1093/infdis/jiad319.
6
Immune response after SARS-CoV-2 vaccination in patients with inflammatory immune-mediated diseases receiving immunosuppressive treatment.
Allergy Asthma Clin Immunol. 2023 Aug 19;19(1):71. doi: 10.1186/s13223-023-00832-0.
7
Immunogenicity of an mRNA-Based COVID-19 Vaccine among Adolescents with Obesity or Liver Transplants.
Vaccines (Basel). 2022 Nov 4;10(11):1867. doi: 10.3390/vaccines10111867.
8
SARS-CoV-2 and Influenza Vaccines in People with Excessive Body Mass-A Narrative Review.
Life (Basel). 2022 Oct 17;12(10):1617. doi: 10.3390/life12101617.
9
The metabolic hormone adiponectin affects the correlation between nutritional status and pneumococcal vaccine response in vulnerable indigenous children.
PLoS One. 2022 Jul 21;17(7):e0270736. doi: 10.1371/journal.pone.0270736. eCollection 2022.
10
A Prospective Study Investigating the Impact of Obesity on the Immune Response to the Quadrivalent Influenza Vaccine in Children and Adolescents.
Vaccines (Basel). 2022 Apr 29;10(5):699. doi: 10.3390/vaccines10050699.
本文引用的文献
1
Maternal and child undernutrition and overweight in low-income and middle-income countries.
Lancet. 2013 Aug 3;382(9890):427-451. doi: 10.1016/S0140-6736(13)60937-X. Epub 2013 Jun 6.
2
Overweight and obese adult humans have a defective cellular immune response to pandemic H1N1 influenza A virus.
Obesity (Silver Spring). 2013 Nov;21(11):2377-86. doi: 10.1002/oby.20383. Epub 2013 May 30.
3
Phase 2 assessment of the safety and immunogenicity of two inactivated pandemic monovalent H1N1 vaccines in adults as a component of the U.S. pandemic preparedness plan in 2009.
Vaccine. 2012 Jun 13;30(28):4240-8. doi: 10.1016/j.vaccine.2012.04.044. Epub 2012 Apr 23.
4
Association between obesity and vulnerability and serologic response to influenza vaccination in older adults.
Vaccine. 2012 Jun 6;30(26):3937-3943. doi: 10.1016/j.vaccine.2012.03.071. Epub 2012 Apr 3.
5
Immunogenicity and safety of H1N1 vaccination in anorexia nervosa--results from a pilot study.
Int J Eat Disord. 2012 Jan;45(1):146-9. doi: 10.1002/eat.20908. Epub 2011 Feb 22.
6
Diet-induced obesity dramatically reduces the efficacy of a 2009 pandemic H1N1 vaccine in a mouse model.
J Infect Dis. 2012 Jan 15;205(2):244-51. doi: 10.1093/infdis/jir731. Epub 2011 Dec 5.
7
Obesity is associated with impaired immune response to influenza vaccination in humans.
Int J Obes (Lond). 2012 Aug;36(8):1072-7. doi: 10.1038/ijo.2011.208. Epub 2011 Oct 25.
8
Obesity is associated with higher risk of intensive care unit admission and death in influenza A (H1N1) patients: a systematic review and meta-analysis.
Obes Rev. 2011 Aug;12(8):653-9. doi: 10.1111/j.1467-789X.2011.00864.x. Epub 2011 Apr 4.
9
A novel risk factor for a novel virus: obesity and 2009 pandemic influenza A (H1N1).
Clin Infect Dis. 2011 Feb 1;52(3):301-12. doi: 10.1093/cid/ciq152. Epub 2011 Jan 4.
10
Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010.
MMWR Recomm Rep. 2010 Aug 6;59(RR-8):1-62.
Zotero 插件